

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(formerly known as China Pharmaceutical Group Limited 中國製藥集團有限公司)

(Incorporated in Hong Kong under the Companies Ordinance)

(Stock code: 1093)

SALE OF EXISTING SHARES BY A SUBSTANTIAL SHAREHOLDER

CSPC Pharmaceutical Group Limited (the “**Company**”) makes this announcement in accordance with Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance.

The board of directors (the “**Board**”) of the Company has been informed by Jinling Investment Limited (“**Jinling**”), being a substantial shareholder (as defined under the Listing Rules) of the Company, that on 26 April 2013, Jinling entered into an agreement with third parties independent from the Company in relation to the sale of 332,800,000 shares in the Company (the “**Sale Shares**”) at a price of HK\$3.60 each (the “**Sale**”). The Sale Shares represent approximately 12.21% of the total issued share capital of the Company as at the date of this announcement.

Immediately before the completion of the Sale, the shareholding of Jinling is approximately 29.05% of the total issued share capital of the Company. Jinling is a wholly owned subsidiary of Massive Top Limited (“**MTL**”). Immediately before the completion of the Sale, MTL, through its wholly owned subsidiaries (consisting of Jinling, China Charmaine Pharmaceutical Company Limited, Massive Giant Group Limited and Joyful Horizon Limited), is interested in approximately 74.64% of the total issued share capital of the Company.

Immediately upon the completion of the Sale, the shareholding of Jinling will be reduced to approximately 16.84% of the total issued share capital of the Company, and the indirect interest of MTL through its wholly owned subsidiaries referred to above in the Company will be reduced to approximately 62.43% of the total issued share capital of the Company.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

For and on behalf of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 26 April 2013

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. FENG Zhenying, Mr. CHAK Kin Man, Mr. PAN Weidong, Mr. ZHAO John Huan, Mr. WANG Shunlong, Mr. WANG Huaiyu, Mr. LU Jianmin and Mr. WANG Zhenguo as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. HUO Zhenxing, Mr. QI Moujia, Mr. GUO Shichang, Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo and Mr. ZHANG Fawang as independent non-executive directors.